ICLR ICON PLC
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1060955
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.4%
TTM net income YoY5.0%
TTM EPS YoY25.8%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR-2.8%
Margins
Gross margin23.5%
Operating margin5.3%
Net margin5.4%
FCF margin10.3%
EBITDA margin9.7%
Returns
ROE5.0%
ROA2.8%
ROIC (approx.)3.0%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets43.8%
Debt / equity0.37x
Current ratio1.32x
Interest coverage2.06x
Cash quality & payout
Operating cash flow / net income2.29x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $8.25B | $8.19B | $8.05B | $7.74B | $5.48B |
| Cost of revenue | $6.08B | $5.82B | $5.71B | $5.53B | $3.97B |
| Gross profit | $2.18B | $2.37B | $2.35B | $2.21B | $1.51B |
| SG&A expense | $780.14M | $728.35M | $768.56M | $778.75M | $585.33M |
| Operating income | $442.85M | $1.03B | $904.66M | $795.24M | $378.53M |
| Interest expense | $197.49M | $237.24M | $336.70M | $229.73M | $182.42M |
| Pretax income | $252.47M | $803.76M | $572.98M | $567.85M | $196.68M |
| Income tax | $23.13M | $64.63M | $18.39M | $59.41M | $41.33M |
| Net income | $229.34M | $739.13M | $554.21M | $505.30M | $153.19M |
| EBITDA | $825.84M | $1.52B | $1.49B | $1.36B | $693.52M |
| EPS (basic) | 2.92 | 8.96 | 6.75 | 6.20 | 2.28 |
| EPS (diluted) | 2.90 | 8.90 | 6.70 | 6.13 | 2.25 |
| Weighted avg. shares (diluted) | 78.97M | 83.03M | 82.72M | 82.47M | 68.07M |
| Balance sheet | |||||
| Cash & equivalents | $647.29M | $538.78M | $378.10M | $288.77M | $752.21M |
| Short-term investments | $0 | $0 | $1.95M | $1.71M | $1.71M |
| Receivables | $1.47B | $1.39B | $1.76B | $1.73B | $1.34B |
| Inventory | — | — | — | — | $5.80M |
| Current assets | $3.50B | $3.28B | $3.29B | $3.23B | $2.94B |
| PP&E, net | $395.72M | $382.88M | $361.18M | $350.32M | $336.44M |
| Goodwill | $8.73B | $9.05B | $9.02B | $8.97B | $9.04B |
| Intangibles | $3.25B | $3.56B | $3.86B | $4.28B | $4.71B |
| Total assets | $16.27B | $16.63B | $16.86B | $17.19B | $17.39B |
| Current liabilities | $3.20B | $2.64B | $2.73B | $2.69B | $2.48B |
| Long-term debt | $2.87B | $3.40B | $3.67B | $4.60B | $5.38B |
| Total debt | $2.87B | $3.40B | $3.67B | $4.60B | $5.38B |
| Total liabilities | $7.08B | $7.19B | $7.65B | $8.69B | $9.32B |
| Shareholders' equity | $9.19B | $9.44B | $9.21B | $8.53B | $8.07B |
| Net debt | $2.23B | $2.86B | $3.29B | $4.31B | $4.63B |
| Shares outstanding | 76.57M | 80.76M | 82.50M | 81.72M | 81.55M |
| Cash flow statement | |||||
| Operating cash flow | $1.04B | $1.29B | $1.16B | $563.32M | $829.14M |
| Capital expenditure | $174.21M | $168.06M | $140.69M | $142.16M | $93.75M |
| Free cash flow | $861.99M | $1.12B | $1.02B | $421.15M | $735.39M |
| Investing cash flow | -$187.53M | -$266.79M | -$226.65M | -$145.87M | -$6.02B |
| Financing cash flow | -$771.26M | -$837.18M | -$844.04M | -$864.17M | $5.11B |
| Depreciation & amortization | $383.00M | $488.50M | $585.95M | $569.51M | $314.99M |
| Stock-based compensation | $102.04M | $45.87M | $55.67M | $70.52M | $133.84M |
| Share buybacks | $750.00M | $500.00M | $0 | $99.98M | $0 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.